Document Detail

Molecular alterations underlying eosinophilic and mast cell malignancies.
MedLine Citation:
PMID:  22204765     Owner:  NLM     Status:  In-Data-Review    
Eosinophilic and mast cell disorders are uncommon hematologic entities, but they can carry significant morbidity and lead to devastating end-organ sequelae. In the past ten years, extensive work has led to the discovery of certain molecular abnormalities underlying a subset of these diseases. A significant minority of patients with clonal eosinophilia carry abnormal gene fusions involving PDGFRA, PDGFRB, and FGFR1. These findings have been quite significant, as those individuals with a FIP1L1-PDGFRA fusion have an exquisite susceptibility to tyrosine kinase inhibitors (TKIs), such as imatinib mesylate. Imatinib leads to a rapid remission in these patients and aborts the clinical trajectory of the disease. Unfortunately, TKIs have not been shown to be particularly active in the case of mastocytosis, although the majority of patients with mastocytosis carry a c-KIT alteration, a target of agents such as imatinib. The reason for this decreased sensitivity to TKIs is related to the resistance of the D816V variant of c-KIT, found in the majority of patients with mastocytosis. Nevertheless, investigation is ongoing to define new molecular lesions in these diseases, and potentially new targets for therapy. Clinical trials are also investigating other novel small molecules that may have efficacy against targets currently resistant to imatinib and other TKIs.
Hossein Sadrzadeh; Omar Abdel-Wahab; Amir T Fathi
Related Documents :
22776915 - The tall cell variant of papillary thyroid carcinoma: clinical and pathological feature...
21905255 - Vibratory perception threshold in young and middle-aged patients at high risk of knee o...
22361625 - Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features a...
22246065 - Evaluation of brugada syndrome by cardiac magnetic resonance.
24266305 - Determinants of bone mineral density in patients on haemodialysis or peritoneal dialysi...
2261415 - Oc125 immunoscintigraphy in ovarian carcinoma: a comparison with alternative methods of...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Discovery medicine     Volume:  12     ISSN:  1944-7930     ISO Abbreviation:  Discov Med     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101250006     Medline TA:  Discov Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  481-93     Citation Subset:  IM    
Center for Leukemia and the Bone Marrow Transplant Unit, Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Advances in the understanding of mechanisms and therapeutic use of bortezomib.
Next Document:  The pathogenesis of progressive multifocal leukoencephalopathy.